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Background: Recent evidence points to an increased incidence of new-onset diabetes and a negative impact on
glucose parameters with statin use. This study examined the safety of ezetimibe vs placebo for change from
baseline to week 24 in HbA1c (primary endpoint), glycoalbumin, and fasting plasma glucose (secondary endpoints)
in Japanese subjects with type 2 diabetes and hypercholesterolemia.
Methods: This was a randomized, double-blind, placebo-controlled, parallel-group, multi-site trial. Adults with type 2
diabetes and hypercholesterolemia whose LDL-C measured <140 mg/dl (subjects receiving lipid-lowering drugs) or
<160 mg/dl (subjects not receiving lipid-lowering drugs) at the start of the screening phase, were randomized after a
5-week wash-out period to ezetimibe 10 mg or placebo (1:1) for 24 weeks. Changes in HbA1c, glycoalbumin and
fasting plasma glucose from baseline to week 24 were evaluated. The non-inferiority margin was set at 0.5% for HbA1c.
Results: Overall, 152 subjects were randomized (75 to ezetimibe and 77 to placebo). From baseline to 24 weeks, HbA1c
significantly increased in both the ezetimibe and placebo groups (between-treatment difference 0.08 [95% CI: −0.07 to
0.23]). Ezetimibe was statistically non-inferior to placebo. At 24 weeks, the mean change from baseline in glycoalbumin
levels (between-treatment differences 0.00 [95% CI: −0.47, 0.47]) and fasting plasma glucose (between-treatment
differences −4.8 [95% CI: −12.1, 2.1]) were similar in both treatment groups.
Conclusions: These results suggest that ezetimibe 10 mg does not result in dysregulation of glucose metabolism in
Japanese patients with type 2 diabetes and hypercholesterolemia over 24 weeks of treatment.
Trial registration: ClinicalTrials.gov identifier NCT01611883.
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While diabetes, hypertension and hypercholesterolemia
are each independent risk factors for coronary artery dis-
ease (CAD), concomitant occurrence of these factors may
lead to a cumulative increase in CAD risk [1]. Manage-
ment of these risk factors is important for reducing the
risk of atherosclerosis and the risk of ischemic heart dis-
ease and CAD. In addition to lipid management and blood
pressure control, glycemic control is a basic component in* Correspondence: taro.kakikawa@merck.com
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diabetes self-management, education, exercise and im-
proved diet, the latter elements being the cornerstones of
treatment for diabetes and lipids. As such, it is important
that glucose metabolism not be adversely affected when
patients take lipid-lowering treatment.
Post-hoc analyses of large clinical trials and meta-
analyses have demonstrated a dose- and potency-
dependent effect for increased incidence of new-onset dia-
betes and mild elevation of hemoglobin A1c (HbA1c) and
fasting plasma glucose with statin use [2-7]. However, it
was determined that the benefits of reducing the risk of car-
diovascular events with statin use significantly outweigh thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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new-onset diabetes [8]. Ezetimibe is an inhibitor of a small
intestine cholesterol transporter. It lowers low-density lipo-
protein cholesterol (LDL-C) by 15-20% through inhibition
of exogenous and biliary cholesterol absorption in the di-
gestive tract by inhibiting the Niemann-Pick C1-Like 1 in
the brush border of enterocytes [9,10]. A significant reduc-
tion in insulin resistance and/or fatty liver have been re-
ported in small clinical trials using the combination of
pravastatin with ezetimibe [11] or ezetimibe monotherapy
[12,13]. However, other small studies have observed no
changes in parameters of glucose metabolism and insulin
sensitivity with ezetimibe monotherapy [14-16]. Limited
data suggest that ezetimibe, whether added to a statin or
used as a monotherapy, does not have an adverse effect on
glucose metabolism [17,18]. However, in light of recent
findings regarding the increased incidence of new-onset
diabetes and the impact on glucose parameters with the
use of statins [2-7], it is important to assess any poten-
tial for these same issues with ezetimibe use. This study
was conducted to prospectively examine the effects of
ezetimibe on glucose metabolism in patients with type 2
diabetes and hypercholesterolemia.
The primary objective of this study was to examine
the safety of ezetimibe compared with placebo with re-
gard to change in HbA1c from baseline to week 24 in
subjects with type 2 diabetes and hypercholesterolemia.
Secondary objectives included comparing ezetimibe to
placebo in subjects with type 2 diabetes and hyperchol-
esterolemia for change in glycoalbumin and fasting
plasma glucose from baseline to week 24; the proportion
of patients having onset of “exacerbation of diabetes melli-
tus” (assessed by index of blood glucose control, changes
in diabetes medications, and compliance to diet and exer-
cise therapy); the proportion of patients with changes to
diabetes medications due to worsening of diabetes.
Methods
Study design
This was a randomized, double-blind, placebo-controlled,
parallel-group, multi-site trial (protocol number: PN367,
Additional file 1; ClinicalTrials.gov identifier NCT01611883)
of ezetimibe in subjects with type 2 diabetes and hyper-
cholesterolemia carried out at 19 sites in Japan and con-
ducted in conformance with Good Clinical Practice and
the Declaration of Helsinki between August 2012 and
January 2014. The protocol was approved by the institu-
tional review boards for each study site (Japanese Asso-
ciation for the Promotion of State of the Art in
Medicine - The Second Institutional Review Board;
Tokushukai Group Institutional Review Board; Hirokuni
Hospital Institutional Review Board; Doujin Memorial
Foundation Meiwa Hospital Institutional Review Board;
Clinical Research Promotion Network Japan InstitutionalReview Board; Hatamoto Institutional Review Board). All
patients provided written, informed consent prior to en-
tering the study. Each subject participated in the trial for
approximately 33 weeks from the time the subject signed
the informed consent form through the final contact. After
screening, eligible subjects stopped any current lipid-
lowering medications for 5 weeks prior to receiving
assigned treatment for approximately 24 weeks. Ezetimibe
10 mg or placebo was administered orally once daily and
follow-up visits occurred at 4, 12, 20 and 24 weeks of
treatment. Serious adverse events were monitored from
the time informed consent was obtained until 30 days
after the administration of the last dose of study drug.
Subjects
Subjects with a diagnosis of type 2 diabetes mellitus and
hypercholesterolemia aged 20 to 75 years were selected
to participate in the trial, including those undergoing
treatment with oral anti-diabetic drugs or insulin or
both, and who had no change in the type, dose, and regi-
men of drugs for the treatment of diabetes within
12 weeks before the start of the screening phase. How-
ever, small changes in insulin dosing +/−5U were accept-
able. Subjects undergoing diet and exercise therapy with
no change in either therapy within 4 weeks before the
start of the screening phase (however, exercise therapy
was not necessarily applicable in the case of patients
with coexisting conditions judged not appropriate to
meet this criterion). Subjects were included whose
LDL-C measured at the start of the screening phase <
140 mg/dl if they had been receiving lipid lowering
drugs; in subjects who had not been receiving lipid low-
ering drugs, LDL-C measures < 160 mg/dl were required.
At 1 week prior to randomization, all subjects were re-
quired to have LDL-C level ≥ 120 mg/dl and < 160 mg/dl
in order to participate in the study. Subjects were excluded
if their triglyceride value exceeded 400 mg/dl, HbA1c
value was ≥8.4%, (HbA1c was recorded in the National
Glycohemoglobin Standardization Program [NGSP]), and/
or fasting plasma glucose was ≥170 mg/dl at screening or
1 week prior to randomization. Subjects were excluded if
they had history of coronary heart disease (CHD), stroke,
or arteriosclerosis obliterans; if they had hypercholesterol-
emia associated with hypothyroidism; or if they had active
or severe hepatic disease. Concomitant therapy with other
lipid modifying therapies including statins, fibrates, niacin,
cyclosporine, systemic corticosteroids, and investigational
drugs was prohibited.
Safety and efficacy endpoints
The primary endpoint of this study was to examine the
safety of ezetimibe compared with placebo with regard
to change in HbA1c from baseline to week 24. Second-
ary endpoints included comparing ezetimibe to placebo
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from baseline to week 24. Additionally, the proportion
of subjects having exacerbation of diabetes mellitus (ex-
acerbation of diabetes mellitus was judged by the investi-
gator taking into account the blood glucose control
indices, diabetes medications, and compliance to diet
and exercise therapy) and the proportion of subjects
with changes in diabetes medication due to worsening of
diabetes was calculated (small changes in insulin dosing
±5U were excluded). Additional safety was monitored
through collection of adverse events (AEs), adverse drug
reactions, hematology (white blood cell count, red blood
cell count, Hb, hematocrit, platelet count), biochemistry
(aspartate aminotransferase, alanine aminotransferase,
gamma glutamyl transpeptidase, alkaline phosphatase,
lactate dehydrogenase, creatine phosphokinase, total bili-
rubin, direct bilirubin, total protein, blood urea nitrogen,
uric acid, creatinine, Na, K, Cl) and vital signs (body
weight, blood pressure, pulse) throughout the study. For
efficacy endpoints the percent change from baseline to
week 24 in serum lipids, including LDL-C, estimated by
the Friedewald equation, total cholesterol, triglycerides,
and high-density lipoprotein cholesterol (HDL-C) were
measured. Non-HDL-C was calculated by subtracting
HDL-C from total cholesterol. All laboratory measure-
ments, including glucose metabolism and lipid parame-
ters, were conducted at a central laboratory.
Statistical analysis
One-hundred-forty eight subjects were planned for en-
rollment with at least 45 (30%) receiving insulin. For the
primary safety hypothesis of this study, the difference
between the ezetimibe and placebo groups in the least
squares mean change in HbA1c from baseline to
24 weeks after treatment was assumed to be 0.1%, with
standard deviation of 0.7% and a non-inferiority margin
of 0.5%. The standard deviation and between groups dif-
ference were determined using a previous open-label
study (a Phase III, trial in diabetic mellitus subjects with
hypercholesterolemia) which provided a limited number
of patients. The non-inferiority margin was given as a
clinically meaningful exacerbation of diabetes control in
medical practice. With this hypothesis, the number of
subjects per group was projected to be 66 with a two-
sided 5% (one-sided 2.5%) probability of type 1 error, 90%
power, and 1:1 allocation to each of the groups. The sam-
ple size was set to 148 to take into account a 10% dropout
rate. There is only one primary hypothesis for this study;
therefore, the issue of multiplicity will not occur.
The data set for the statistical analysis of safety is the
per protocol set (PPS). Missing values were not replaced
with other values. The full analysis set (FAS) was used
for the sensitivity analysis of the primary trial objective
and was defined as all randomized subjects meeting theinclusion criteria who received study drug and for whom
a baseline and at least one post-baseline measurement
was obtained. This was the data set for the efficacy ana-
lysis. Missing values were not replaced with other values.
The PPS was defined as all randomized subjects meeting
inclusion criteria who were not excluded from the FAS
and were at least 75% compliant with study medication.
The all subjects as treated (ASaT) group was defined as
all subjects who took at least one dose of study drug
during the treatment period. The ASaT was used for the
analysis of AEs.
The longitudinal analysis of covariance was used to as-
sess the primary (HbA1c) and secondary safety end-
points (glycoalbumin and fasting plasma glucose).
Baseline, treatment group, HbA1c (2 categories: < 7.4%
and ≥7.4% to < 8.4%), insulin use (2 categories: yes, no),
time, and “time × treatment group” interaction were in-
cluded in the model. So as not to place restriction on
the time-course curve of mean values, time was a cat-
egorical variable. Between-group difference in mean
amount of change from baseline at measurement time
points was estimated and tested. Correlation between
time-course measured values was modeled using an un-
structured covariance matrix, but if this calculation did
not converge, Toeplitz was used for correlation. Based
on the above unstructured model, the difference in least
squares (LS) mean from the placebo group and the 95%
confidence interval (CI) were calculated. The LS mean
value of the amount of change from baseline with each
group and the 95% CI were also calculated. As sensitivity
analysis of the primary endpoint, the same analysis was
conducted with the FAS. A between-group comparison
was conducted using Fisher’s exact test for the propor-
tion of subjects with “exacerbation of diabetes”. A
between-group comparison using Fisher’s exact test was
also conducted for the proportion of subjects with
changes in diabetes medications due to worsening of
diabetes. Summary statistics with standard deviations
were calculated for demographic and baseline character-
istics and the number of subjects with AEs and the inci-
dence of AEs were summarized by treatment group and
by system organ class and event. The percent change
from baseline to each measurement time point was cal-
culated by treatment group for lipid parameters using
the same longitudinal analysis of covariance used for the
primary safety endpoint. Lipids included LDL-C, total
cholesterol, triglycerides, HDL-C, and non-HDL-C. No
adjustments were made for multiplicity.
Results
A total of 342 subjects were screened, resulting in 152
randomized to treatment (75 to ezetimibe 10 mg and 77
to placebo; Figure 1). In each treatment group, only 1
subject discontinued due to an AE. No patients were
Figure 1 Patient flow through the study.
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demographics and clinical characteristics were similar
between treatment groups (Table 1). Approximately 2/3
of subjects were male, the mean (± standard deviation
[SD]) age was 60 (±10) years, with a mean (± SD) body
mass index of 26 (±5) kg/m2. The vast majority (95%) of
subjects had coexisting diseases. There was no notable
difference observed between the two groups in coexisting
diseases or the use of concomitant medications (Table 1).
At baseline mean HbA1c was 7.0%, glycoalbumin was
17.3%, and fasting plasma glucose was 126.3 mg/dL.
The mean baseline values and change from baseline in
blood glucose control indices in the ezetimibe 10 mg
and placebo groups are shown in Table 2. Over the
course of the 24 weeks of treatment, HbA1c signifi-
cantly increased from baseline in both the ezetimibe
10 mg and placebo groups (Figure 2). At 24 weeks, the
least-squares (LS) mean (95% CIs) changes from base-
line in HbA1c were 0.22 (0.11 to 0.34) and 0.14 (0.03
to 0.25) for the ezetimibe 10 mg and placebo groups,
respectively (Table 2). The between-treatment difference
in the change from baseline was 0.08 (−0.07 to 0.23). The
ezetimibe 10 mg group was statistically non-inferior to the
placebo group, compared with the pre-defined non-
inferiority margin of 0.5 (Table 2). The sensitivity analysis
was consistent with the primary results, demonstrating
non-inferiority of ezetimibe. Results were generally con-
sistent across subgroups defined by baseline HbA1c level
(<7.4%, vs. ≥7.4% to <8.4%) and by insulin administration
at baseline (yes vs. no; data not shown).
At 24 weeks, the LS mean changes (95% CIs) from base-
line in glycoalbumin were −0.02 (−0.37, 0.34) and −0.02(−0.37, 0.33) for the ezetimibe 10 mg and placebo groups,
respectively (Table 2). Over the course of the 24 weeks of
treatment, changes from baseline in glycoalbumin levels in
both treatment groups were similar (Figure 3). The
between-treatment difference in the change from baseline
at 24 weeks was (0.00; 95% CI: −0.47, 0.47; Table 2).
At 24 weeks, the LS mean changes (95% CIs) from base-
line in fasting plasma glucose were 6.6 (1.1, 12.1) and 11.4
(6.1, 16.7) for the ezetimibe 10 mg and placebo groups, re-
spectively (Table 2). Over the course of the 24 weeks of
treatment, fasting plasma glucose significantly increased
from baseline in both treatment groups (Figure 4). The
between-treatment difference in the change from baseline
at 24 weeks was (−4.8; 95% CI: −12.1, 2.1; Table 2).
There was no significant difference in exacerbation of
diabetes between treatment groups (p = 0.78). Seven sub-
jects (9%) in the ezetimibe group and 6 subjects (8%) in
the placebo group experienced exacerbation of diabetes.
Similarly, there was no significant difference between
groups in the proportion of subjects with changes to dia-
betes medications due to worsening of diabetes (p = 0.37).
Seven subjects (9%) in the ezetimibe group and 4 subjects
(5%) in the placebo group made changes to their diabetes
medications due to worsening of their diabetes during the
study period.
The percent changes from baseline to 24 weeks in
LDL-C, total cholesterol, triglycerides, HDL-C and non-
HDL-C are shown in Figure 4. After 24 weeks of treat-
ment, the change from baseline was statistically significant
for all 5 lipid parameters in subjects treated with ezetimibe
10 mg (P < 0.05) but was not statistically significant in sub-
jects who received placebo. The percent differences (95%
Table 1 Baseline demographics and clinical characteristics
Ezetimibe Placebo Total
Subjects in population 75 77 152
Male, n (%) 46 (61.3) 48 (62.3) 94 (61.8)
Mean age, yrs (SD) 59.3 (10.8) 60.0 (9.7) 59.6 (10.2)
Mean body mass index, kg/m2 (SD) 26.2 (5.3) 25.7 (3.9) 25.9 (4.6)
Coexisting diseases, yes; n (%) 70 (93.3) 74 (96.1) 144 (94.7)
Selected coexisting diseases, n (%):
Cardiac disease other than CHD 3 (4.0) 4 (5.2) 7 (4.6)
Hypertension 37 (49.3) 35 (45.5) 72 (47.4)
Hepatic steatosis 24 (32.0) 26 (33.8) 50 (32.9)
Hyperuricaemia 6 (8.0) 7 (9.1) 13 (8.6)
Obesity 2 (2.7) 1 (1.3) 3 (2.0)
Concomitant medications, yes; n (%) 75 (100) 77 (100) 152 (100)
Selected concomitant medications, n (%):
Oral anti diabetes agents 70 (93.3) 72 (93.5) 142 (93.4)
Dipeptidyl peptidase-4 inhibitors 39 (52.0) 29 (37.7) 68 (44.7)
Sulfonylureas 27 (36.0) 22 (28.6) 49 (32.2)
Glinides 3 ( 4.0) 10 (13.0) 13 (8.6)
Thiazolidine 12 (16.0) 9 (11.7) 21 (13.8)
Biguanides 34 (45.3) 28 (36.4) 62 (40.8)
Alpha-glucosidase inhibitors 24 (32.0) 24 (31.2) 48 (31.6)
Thiazolidine + Biguanides 1 (1.3) - 1 (0.7)
Glinides + Alpha-glucosidase inhibitors 2 (2.7) - 2 (1.3)
Insulin administration yes; n (%) 23 (30.7) 24 (31.2) 47 (30.9)
Hypertension agents 35 (46.7) 30 (39.0) 65 (42.8)
Calcium channel blocker 19 (25.3) 15 (19.5) 34 (22.4)
Beta blocker 2 (2.7) 1 (1.3) 3 (2.0)
Alpha blocker 5 (6.7) 2 (2.6) 7 (4.6)
ARB 22 (29.3) 17 (22.1) 39 (25.7)
Diuretic 3 (4.0) 1 (1.3) 4 (2.6)
ACE inhibitor 2 (2.7) 4 (5.2) 6 (3.9)
ARB + Diuretic 3 (4.0) 1 (1.3) 4 (2.6)
ARB + Calcium channel blocker 3 (4.0) 3 (3.9) 6 (3.9)
Mean duration of diabetes, months (SD) 88.9 (74.0) 94.9 (93.8) 92.0 (84.4)
Mean HbA1c, % (SD) 7.0 (0.6) 7.0 (0.6) 7.0 (0.6)
<7.4%, n (%) 56 (74.7) 58 (75.3) 114 (75.0)
≥7.4%, <8.4%, n (%) 19 (25.3) 19 (24.7) 38 (25.0)
Mean glycoalbumin, % (SD) 17.3 (2.3) 17.4 (2.6) 17.3 (2.4)
Mean fasting plasma glucose, mg/dL (SD) 125.7 (22.2) 126.9 (17.3) 126.3 (19.8)
Mean LDL-C, mg/dL (SD) 138.6 (11.2) 139.4 (10.4) 139.0 (10.8)
Mean total cholesterol, mg/dL (SD) 217.6 (16.2) 219.0 (21.1) 218.3 (18.8)
Mean triglycerides, mg/dL (SD) 119.6 (57.3) 129.5 (63.8) 124.6 (60.7)
Mean HDL-C, mg/dL (SD) 55.0 (13.5) 53.7 (12.8) 54.3 (13.1)
Mean non-HDL-C, mg/dL (SD) 162.6 (15.2) 165.3 (16.4) 164.0 (15.9)
ARB = angiotensin receptor blocker; ACE = angiotensin converting enzyme; HbA1c = hemoglobin A1c HDL-C = high-density lipoprotein cholesterol; LDL-C = low-
density lipoprotein cholesterol.
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Table 2 Change from baseline to 24 weeks in glucose parameters
Baseline Week 24 Change
Treatment (n) Mean (SE) Mean (SE) Mean (SE) LS Mean (95% CI) P-value
HbA1c (%) Ezetimibe (n = 69) 6.94 (0.07) 7.14 (0.10) 0.20 (0.06) 0.22 (0.11, 0.34) <0.001
Placebo (n = 75) 6.96 (0.06) 7.09 (0.07) 0.13 (0.05 0.14 (0.03, 0.25) 0.015
Ezetimibe vs Placebo Difference in LS mean (95% CI) 0.08 (−0.07, 0.23) 0.281
Glyocalbumin (%) Ezetimibe (n = 69) 17.16 (0.26) 17.14 (0.30) −0.02 (0.17) −0.02 (−0.37, 0.34) 0.919
Placebo (n = 75) 17.21 (0.27) 17.20 (0.29) −0.01 (0.17) −0.02 (−0.37, 0.33) 0.918
Ezetimibe vs Placebo Difference in LS mean (95% CI) 0.00 (−0.47, 0.47) 1.000
Fasting plasma glucose (mg/dL) Ezetimibe (n = 69) 124.7 (2.6) 128.0 (2.8) 3.3 (3.0) 6.6 (1.1, 12.1) 0.019
Placebo (n = 75) 126.7 (2.0) 135.4 (2.9) 8.7 (2.5) 11.4 (6.1, 16.7) <0.001
Ezetimibe vs Placebo Difference in LS mean (95% CI) −4.8 (−12.1, 2.5) 0.194
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24 weeks were statistically significant except for HDL-C:
LDL-C: −21.05% (−25.06, −17.03) P < 0.001; total choles-
terol: −13.54% (−16.66, −10.42) P < 0.001; HDL-C: 2.45%
(−1.71, 6.61) P = 0.25; triglycerides: −11.36% (−21.27, −1.44)
P = 0.03; and non-HDL-C: −19.07% (−22.71, −15.43) P <
0.001.
A summary of AEs for the ASaT population is shown
in Table 3. Approximately half (49.3%) of subjects
treated with ezetimibe 10 mg reported experiencing an
AE and nearly 2/3 (64.9%) of subjects receiving placebo
reported experiencing an AE during the study period.
Three subjects (4.0%) in the ezetimibe 10 mg group and
1 subject (1.3%) in the placebo group reported a drug-
related AE. There were 2 subjects (2.7%) in the ezeti-
mibe 10 mg group (1 cataract and 1 abdominal pain)
and 5 subjects (6.5%) in the placebo group (2 cases ofFigure 2 Change from baseline in HbA1c (%) over 24 weeks of
treatment with ezetimibe 10 mg or placebo (PPS).angina—one prior to study participation and one after
study completion; 1 accidental overdose, 1 ankle frac-
ture, 1 spinal osteoarthritis) that reported serious AEs.
None of these AEs were considered related to study
drug, nor were there any deaths in either group. The
incidence of AEs of interest was generally similar be-
tween treatment groups. No serious AEs, deaths or
AEs leading to study discontinuation occurred in this
study.Discussion
The results of this study showed that the ezetimibe
10 mg group was statistically non-inferior to the placebo
group with respect to change in HbA1c. Over the course
of the 24 weeks of treatment, changes from baseline in
glycoalbumin and fasting plasma glucose levels in both
treatment groups were similar. In addition, differences
in exacerbation of diabetes or changes to patients’ dia-
betes medications due to worsening of their diabetes
during the study period did not change significantly.
However, differences in change from baseline lipid pa-
rameters between ezetimibe and placebo were statisti-
cally significant at 24 weeks, except for HDL-C.
Ezetimibe was generally safe and well-tolerated.
Results of 2 meta-analyses suggested that treatment
with statins may be associated with a small (9%) in-
creased risk for developing diabetes [4,19]. This was
based on measures of glucose regulation such as HbA1c,
and fasting plasma glucose. However, published informa-
tion regarding the incident relationship of ezetimibe
treatment to glucose regulations and new onset diabetes
is limited. Trials that did report on glucose changes with
ezetimibe treatment included subjects with diabetes or
metabolic syndrome, both populations that may have im-
paired glucose function at study start [20,21]. Therefore, it
is difficult to fully assess the individual impact of ezetimibe
on glucose metabolism based on the published data.
Figure 4 Percent change from baseline to 24 weeks in lipid
parameters (FAS). No patient had triglyceride level >400 mg/dL
after allocation.
Table 3 Summary of adverse events
Ezetimibe Placebo
n (%) n (%)
Subjects in population 75 77
With ≥1 adverse events 37 (49.3) 50 (64.9)
With drug-related adverse events 3 (4) 1 (1.3)
With serious adverse events 2 (2.7) 5 (6.5)
Discontinued due to an adverse event 1 (1.3) 1 (1.3)
Discontinued due to a serious adverse event 0 (0) 1 (1.3)
Figure 3 Change from baseline in A) glycoalbumin (%) and B)
fasting plasma glucose (mg/dL) over 24 weeks of treatment with
ezetimibe 10 mg or placebo (PPS).
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mibe may have positive effects on glycemic control, in-
cluding reduced weight gain, diet-induced hyperglycemia
and insulin resistance [22], improvement in insulin and
plasma glucose response in obese fatty rats [23], and im-
provement in glucose tolerance, increased insulin sensi-
tivity, and protecting the function of beta-cells in
diabetic mice [24]. In addition, one clinical trial showed
that after 12 weeks of treatment with ezetimibe 10 mg
monotherapy, reductions in HbA1c and fasting plasma
glucose were seen in Japanese patients with insulin re-
sistance [25]. These results are consistent with those of
the current trial, suggesting that ezetimibe does not con-
fer an increased risk of glucose dysregulation. However,
in the previous studies that observed neutral changes inparameters of glucose metabolism and insulin sensitivity
with ezetimibe monotherapy, the study populations were
small, limiting the generalizability of the results to larger
populations [14-16]. More recent preliminary data from
two post-hoc, pooled analyses in subjects without dia-
betes suggest that ezetimibe monotherapy or ezetimibe
added to statin does not have a negative effect on
glucose metabolism [17,18].
The magnitude of change from baseline in lipids, includ-
ing LDL-C, total cholesterol, triglycerides and HDL-C,
was consistent with those demonstrated in previous 12-
week trials of ezetimibe monotherapy vs. placebo [26-33].
A meta-analysis of these same trials demonstrated that
ezetimibe monotherapy conferred significant reductions in
LDL-C, triglyceride, and total cholesterol levels as well as
a significant increase in HDL-C level compared with pla-
cebo [34]. Except for the significant HDL-C increases, the
results of the meta-analysis are consistent with those of
the current trial in Japanese patients.
Ezetimibe 10 mg was generally well tolerated. Most
AEs were mild in intensity with few related to treatment.
There were no unexpected AEs reported based on what
has been observed in other clinical trials with ezetimibe
monotherapy [34].
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interpreted with caution. The population was limited to
Japanese patients and may not be generalizable to other
populations. The short-term safety profile of ezetimibe
monotherapy appears to be similar to placebo. This short-
term study limits the ability to extrapolate the results to
long-term profiles. However, the recently completed
IMPROVE-IT trial assessed the incremental cardiovascu-
lar benefit of LDL-C lowering over 7 years with ezetimibe
10 mg added to simvastatin (mainly 40 mg) compared
with simvastatin monotherapy in patients presenting with
acute coronary syndromes [35-37]. The study investigators
reported that the trial met its primary and secondary com-
posite efficacy endpoints.
Conclusions
In conclusion, these data suggest that treatment with
ezetimibe 10 mg does not result in dysregulation of glu-
cose metabolism over 24 weeks in Japanese patients with
type 2 diabetes and hypercholesterolemia. Ezetimibe was
generally well-tolerated with reduction of atherogenic
lipid parameters.
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